Publications by authors named "D Semizarov"
Updated Results from the Retrospective CREST Study on the Safety and Effectiveness of 8-Week Glecaprevir/Pibrentasvir in HCV-Infected Treatment-Naïve Patients with Compensated Cirrhosis.
Adv Ther
December 2024
Article Synopsis
- The study updates findings from the CREST study on the 8-week treatment of glecaprevir/pibrentasvir (GLE/PIB) for patients with chronic hepatitis C and compensated cirrhosis.
- It analyzes 437 patients, showing a high sustained virologic response (SVR12) of 98.9%, especially among those with certain comorbidities and those on other medications.
- The research highlights safety aspects, noting only a small percentage experienced adverse events, and emphasizes variations in healthcare resource use based on patients' employment status and drug use history.
Background And Aims: No direct-acting antiviral is currently approved for acute HCV infection, delaying treatment. We investigated the effectiveness and safety of 8-week glecaprevir/pibrentasvir (G/P) in patients with acute HCV infection.
Approach And Results: This noninterventional, single-arm, retrospective chart review was designed to enroll adults/adolescents with acute HCV infection.
Introduction: An unsafe injection practice is one of the major contributors to new hepatitis C virus (HCV) infections; thus, people who inject drugs are a key population to prioritize to achieve HCV elimination. The introduction of highly effective and well-tolerated pangenotypic direct-acting antivirals, including glecaprevir/pibrentasvir (GLE/PIB), has revolutionized the HCV treatment landscape. Glecaprevir is a weak cytochrome P450 3A4 (CYP3A4) inhibitor, so there is the potential for drug-drug interactions (DDIs) with some opioids metabolized by CYP3A4, such as fentanyl.
View Article and Find Full Text PDFBackground: Conventional healthcare models struggle to engage those at risk of hepatitis C virus (HCV) infection. This international study evaluated point-of-care (PoC) HCV RNA diagnostic outreach and direct-acting antiviral (DAA) treatment for individuals receiving opioid agonist therapy (OAT) in community pharmacies.
Aims: We assessed the effectiveness of a roving nurse-led pathway offering PoC HCV RNA testing to OAT clients in community pharmacies relative to conventional care.
Article Synopsis
- Proton pump inhibitors (PPIs) can reduce the effectiveness of some antiviral treatments for chronic hepatitis C virus (HCV), leading to a study comparing the efficacy of the glecaprevir/pibrentasvir regimen in patients on PPIs versus those not on them.
- Data from 2,369 HCV patients showed similar rates of sustained virologic response (SVR12) at around 97% for both groups, indicating that PPIs do not significantly hinder treatment outcomes.
- However, the bioavailability of glecaprevir was notably reduced in patients using high-dose PPIs, suggesting some impact on drug absorption, but it did not translate to treatment failures.